Advertisement
The bluebird bio Inc stock closed at 4.08 USD, experiencing a sharp decline of 3.22 USD (-44.11%) over the past five days. The company this week, announced that it has signed a deal to be acquired by the private-equity firms Carlyle Group and SK Capital Partners, resulting in the stock’s decline.
On February 21 at 7:50 PM GMT-5, the stock traded within a wide range, reaching a high of 5.65 USD and a low of 4.00 USD during the session. It opened at 4.90 USD, indicating an attempt to recover, but the downward trend continued, pulling the stock to a lower close.
However in the after-hours trading, the decline extended further, with the stock dropping 0.090 USD (2.21%) to 3.99 USD.With a market capitalization of 3.97Cr, bluebird bio remains a relatively small-cap biotech firm, making it more vulnerable to sharp price swings.
Disclaimer: This article is for informational purposes only and does not constitute any financial advice.